Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.

about

Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.

Item

http://www.wikidata.org/entity/Q50119590

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Impact of ritonavir dose and s ...... lax clinical pharmacokinetics.

@en

Impact of ritonavir dose and s ...... lax clinical pharmacokinetics.

@nl

type

Item

label

Impact of ritonavir dose and s ...... lax clinical pharmacokinetics.

@en

Impact of ritonavir dose and s ...... lax clinical pharmacokinetics.

@nl

prefLabel

Impact of ritonavir dose and s ...... lax clinical pharmacokinetics.

@en

Impact of ritonavir dose and s ...... lax clinical pharmacokinetics.

@nl

P1476

Impact of ritonavir dose and s ...... lax clinical pharmacokinetics.

@en

P2093

Ahmed Hamed Salem

http://www.w3.org/2001/XMLSchema#string

Beibei Hu

http://www.w3.org/2001/XMLSchema#string

Kevin J Freise

http://www.w3.org/2001/XMLSchema#string

P2860

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

HIV infection and lymphoma.

Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.

Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments.

Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.

Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers.

Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.

P2888

s00228-017-2403-3

P31

scholarly article

P356

10.1007/S00228-017-2403-3

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29302721

http://www.w3.org/2001/XMLSchema#string